Press

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Oct 25 • 4 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases and its subsidiary, Perception Neuroscience (“Perception”), today announced the completion of enrollment of its Phase 2a clinical trial to evaluate the safety and efficacy of a single intravenous infusion (IV) dose of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of…

Albert Labs provides Corporate Update

Oct 25 • 6 min read

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50), a pharmaceutical drug development company focussed on gaining regulatory approval for active compounds to treat various mental health conditions, has published a corporate update highlighting the progress that has been made since closing its Series A private placement and some information on its future plans and activities. Overview –…

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

Oct 24 • 4 min read

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it has appointed Edward Smith as the Company’s Chief Financial Officer and Aviva Asnis-Alibozek as Vice President, Medical Affairs, effective immediately. Both Mr. Smith and Dr. Asnis-Alibozek will report to Greg Mayes,…

Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited

Oct 24 • 5 min read

Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced that it has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited (“Eleusis”), in an all equity transaction. Under the terms of the agreement, which has been approved…

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Oct 24 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has entered an Investigator-Initiated Clinical Trial Agreement (“CTA”) with Yale University (“Yale”) for the investigation of multiple intravenous doses of DMT for the treatment of depression. The trial’s principal investigator is Professor…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436